Association of low CD4 cell count and intrauterine growth retardation in Thailand

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 4, 2009, Pages 409-413

  Cailhol, Johann ^a   Jourdain, Gonzague ^a,b   Le Coeur, Sophie ^b,c   Traisathit, Patrinee ^d   Boonrod, Kamol ^e   Prommas, Sinart ^f   Putiyanun, Chaiwat ^g   Kanjanasing, Annop ^h   Lallemant, Marc ^a,b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Institut National d'Etudes Démogaphiques   (France)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e Banglamung Hospital   (Thailand)

^f BHUMIBOL ADULYADEJ HOSPITAL   (Thailand)

^g Chiang Kham Hospital   (Thailand)

^h Chachoengsao Hospital   (Thailand)

Author keywords

Antiretroviral therapy; Developing country; HIV intrauterine growth retardation; Immune deficiency; Pregnancy

Indexed keywords

ZIDOVUDINE;

ARTICLE; BODY HEIGHT; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTRAUTERINE GROWTH RETARDATION; INTRAUTERINE INFECTION; MAJOR CLINICAL STUDY; MALE; PREGNANT WOMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THAILAND; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ADULT; DISEASE TRANSMISSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FETAL GROWTH RETARDATION; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 64249155675     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181958560     Document Type: Article

References (29)

1. de Onis M, Blossner M, Villar J. Levels and patterns of intrauterine growth retardation in developing countries. Eur J Clin Nutr. 1998;52: S5-S15.
2. Mclntire DD, Bloom SL, Casey BM, et al. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med. 1999; 340:1234-1238.
3. Leon DA. Fetal growth and adult disease. Eur J Clin Nutr. 1998;52:S72-S78; Discussion S78-S82.
4. Kramer MS. Determinants of low birth weight: methodological assessment and meta-analysis. Bull World Health Organ. 1987;65:663-737.
5. Odegard RA, Vatten LJ, Nilsen ST, et al. Preeclampsia and fetal growth. Obstet Gynecol. 2000;96:950-955.
6. Kunavikatikul C, Sirivatanapa P, Tongsong T, et al. Materno-fetal Medicine, Annual Report. Chiang Mai, Thailand: Chiang Mai university; 2003.
7. Iroha EO, Ezeaka VC, Akinsulie AO, et al. Maternal HIV infection and intrauterine growth: aprospective study in Lagos, Nigeria. West Afr J Med. 2007;26:121-125.
8. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998 Aug;105:836-48.
9. Dreyfuss ML, Msamanga GI, Spiegelman D, et al. Determinants of low birth weight among HIV-infected pregnant women in Tanzania. Am J Clin Nutr. 2001;74:814-826.
10. Ellis J, Williams H, Graves W, et al. Human immunodeficiency virus infection is a risk factor for adverse perinatal outcome. Am J Obstet Gynecol. 2002;186:903-906.
11. Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS. 2000;14:1389-1399.
12. Stratton P, Tuomala RE, Abboud R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:179-186.
13. Verhoeff FH, Brabin BJ, van Buuren S, et al. An analysis of intra-uterine growth retardation in rural Malawi. Eur J Clin Nutr. 2001;55:682-689.
14. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. NEnglJMed. 2000;343:982-991.
15. Tongsong T, Simaraks S, Sirivatanapa P, et al. Study of intrauterine growth from birthweight at Maharaj Nakhon Chiang Mai Hospital. J Med Assoc Thai. 1993;76:482-486.
16. Bryson YJ, Luzuriaga K, Sullivan JL, et al. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med. 1992;327: 1246-1247.
17. Taylor JM, Fahey JL, Detels R, et al. CD4 percentage, CD4 number and CD4:CD8 ratio: which to choose and how to use. J Acquir Immune Defic Syndr Hum Retrovirol. 1989;2:114-124.
18. Lee BN, Ordonez N, Popek EJ, et al. Inflammatory cytokine expression is correlated with the level of human immunodeficiency virus (HIV) transcripts in HIV-infected placental trophoblastic cells. J virol. 1997;71: 3628-3635.
19. Rogerson SJ, Brown HC, Pollina E, et al. Placental tumor necrosis factor alpha but not gamma interferon is associated with placental malaria and low birth weight in Malawian women. Infect Immun. 2003;71:267-270.
20. Chiang Mai University FoM. Materno-Fetal Medicine Annual Report. Faculty of Medicine, Chiang Mai, Thailand; 2003.
21. Traisathit P, Le Coeur S, Mary JY, et al. Gestational age determination and prevention of HIVperinatal transmission. Int J Gynaecol Obstet. 2006;92: 176-180.
22. Department of HIV/AIDS, Department of Reproductive Health and Research. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva, Switzerland: World Health Organization; 2004.
23. Watts DH, Balasubramanian R, Maupin RT, Jr., Delke I, Dorenbaum A, Fiore S, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004;190:506-516.
24. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
25. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune defic Syndr. 2003;32:380-387.
26. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193:1195-1201.
27. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473.
28. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20:2345-2353.
29. Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics. 2007; 119: e900-e906.